---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-047822"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:14:57.583675+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Sana Biotechnology expects to file IND for SC291 in autoimmune diseases in Q4 2023, with clinical data in 2024

## Summary
- Sana expects to file investigational new drug application for SC291 in autoimmune diseases in Q4 2023.
- Clinical data from SC291 in autoimmune diseases expected in 2024.
- Announcement made at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023.

## SEC filing metadata
- accession: 0000950170-23-047822
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017023047822/0000950170-23-047822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017023047822/sana-20230912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-047822
- JSON: https://secwatch.observer/filing/0000950170-23-047822.json
- Plain text: https://secwatch.observer/filing/0000950170-23-047822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.